Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/bmt.2016.112 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Factors affecting posaconazole plasma concentrations: a meta-analysis and systematic review.
Front Pharmacol
December 2024
Department of Clinical Pharmacy, The First Hospital of Hebei Medical University, Shijiazhuang, China.
Background: Posaconazole is a potent antifungal agent widely used to manage invasive fungal infections, especially in immunocompromised individuals. Achieving optimal therapeutic concentrations of posaconazole can be challenging due to interpatient variability, the availability of multiple formulations, and various dosing strategies.
Methods: We conducted a systematic search of PubMed, EMBASE, and the Cochrane Library to identify studies evaluating factors that influence blood concentrations of posaconazole.
Effectiveness of combined proton pump inhibitors and posaconazole prophylaxis against invasive fungal infections in patients with hematologic malignancies: a retrospective study.
Int J Clin Pharm
December 2024
Department of Clinical Pharmacy, The First Hospital of Hebei Medical University, Shijiazhuang, 050000, China.
Background: Posaconazole is widely recommended for preventing and treating invasive fungal infections (IFIs) in immunocompromised patients, especially those with prolonged neutropenia. However, the concentration of the oral suspension formulation can be affected by factors such as co-administration with acid-suppressing medications, influencing its efficacy and safety.
Aim: This study examined the impact of proton pump inhibitors (PPIs) and other factors on posaconazole concentrations and the concentration-to-dose ratio (C/D) while also evaluating adverse drug reactions in patients with hematologic malignancies.
Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Studies Related to Vincristine-Induced Peripheral Neuropathy in Chinese Pediatric ALL Patients.
Clin Pharmacol Ther
February 2025
Infection, Immunity, Inflammation Section, UCL Institute of Child Health, London, UK.
Article Synopsis
- Vincristine can lead to vincristine-induced peripheral neuropathy (VIPN) in children with acute lymphoblastic leukemia (ALL), and this study aimed to understand the factors that affect its pharmacokinetics and pharmacodynamics.
- A total of 79 pediatric patients were analyzed, revealing that certain genetic factors and interactions with other drugs, like posaconazole, significantly influence the metabolism of vincristine and its association with VIPN risk.
- The research suggests that monitoring vincristine levels during treatment is vital for adjusting dosages and personalizing therapy to mitigate the risk of VIPN.
Individualized regimen of Posaconazole oral suspension in Chinese HSCT patients based on population pharmacokinetic model.
Sci Rep
August 2024
Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Pediatric Drug Clinical Evaluation and R&D Research Center of Engineering Technology, Jinan, 250014, China.
To establish a population pharmacokinetic (PopPK) model of posaconazole suspension in Chinese hematopoietic stem cell transplantation (HSCT) patients and to recommend an optimal dosing regimen. A single-center, retrospective, model-based study was conducted in 62 Chinese patients, including 103 with posaconazole plasma concentrations. PopPK analysis using NONMEM software.
View Article and Find Full Text PDFImpact of posaconazole and diltiazem on pharmacokinetics of encorafenib, a BRAF V600 kinase inhibitor for melanoma and colorectal cancer with BRAF mutations.
Clin Transl Sci
December 2023
Early Clinical Development, Pfizer Inc., Boulder, Colorado, USA.
Encorafenib is a potent and selective ATP competitive inhibitor of BRAF V600-mutant kinase approved for patients with BRAF-mutant melanoma and colorectal cancer. Encorafenib is mainly metabolized by cytochrome P450 (CYP) 3A4 in vitro and may be susceptible to drug-drug interactions when co-administered with CYP3A inhibitors or inducers. The primary objective was to assess the impact of the strong CYP3A inhibitor posaconazole (part 1) and the moderate CYP3A and P-gp inhibitor diltiazem (part 2) on encorafenib pharmacokinetics in healthy volunteers following a single 50-mg dose.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!